Emily J Pomeroy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1288266/publications.pdf

Version: 2024-02-01

1040056 1125743 12 514 9 13 citations h-index g-index papers 14 14 14 690 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells. Nature Communications, 2021, 12, 2437.	12.8	50
2	Engineering T cells to enhance 3D migration through structurally and mechanically complex tumor microenvironments. Nature Communications, 2021, 12, 2815.	12.8	73
3	Nonviral genome engineering of natural killer cells. Stem Cell Research and Therapy, 2021, 12, 350.	5.5	18
4	Targeting Ras signaling in AML: RALB is a small GTPase with big potential. Small GTPases, 2020, 11, 39-44.	1.6	8
5	SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis. Oncogene, 2020, 39, 1049-1062.	5.9	13
6	A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy. Molecular Therapy, 2020, 28, 52-63.	8.2	120
7	Implication of <i>ZNF217</i> in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma. Molecular Cancer Therapeutics, 2020, 19, 2528-2541.	4.1	11
8	PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma. Bone, 2020, 136, 115353.	2.9	20
9	Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nature Communications, 2019, 10, 5222.	12.8	135
10	An Indole–Chalcone Inhibits Multidrug-Resistant Cancer Cell Growth by Targeting Microtubules. Molecular Pharmaceutics, 2018, 15, 3892-3900.	4.6	36
11	Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency. Haematologica, 2016, 101, 1190-1199.	3.5	14
12	RALB provides critical survival signals downstream of Ras in acute myeloid leukemia. Oncotarget, 2016, 7, 65147-65156.	1.8	7